Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Current and Projected Market Size of the Osteoporosis Drugs Industry?

In recent times, there has been a consistent expansion in the size of the osteoporosis drugs market. The market is expected to expand from $12.48 billion in 2024 to $12.85 billion in 2025, with an annual compound growth rate (CAGR) of 3.0%. The increase in the past time period can be ascribed to an aging population, heightened consciousness and diagnosis, aspects of lifestyle, governmental strategies, and healthcare policies.

Growth in the osteoporosis drugs market size is anticipated to be steady in the coming years, reaching “$14.2 billion in 2029 with a compound annual growth rate (CAGR) of 2.5%. This growth during the forecast period can be linked to factors like the consistent trends in aging populations, improvements in treatment methodologies, amplified attention to men’s bone health, patient awareness and empowerment, as well as global health policies and insurance plans. The forecast period also predicts trends such as the use of personalized medicine methods, the exploration of combining therapies, emphasis on strategies for preventing fractures, research and development investment in new drug targets, and collaborations for drug advancement.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=9102&type=smp

#Which Factors Are Currently Driving The Growth Of The Osteoporosis Drugs Market?

The increase in osteoporosis cases is predicted to fuel the expansion of the osteoporosis drug market. Osteoporosis is a condition characterized by a decrease in bone mineral density and mass or changes in bone quality or structure. Individuals with a low intake of calcium are more prone to osteoporosis. These drugs for osteoporosis enhance bone mineral density and assist in preventing fractures. For instance, the Australian Institute of Health and Welfare Australia-Government agency reported in June 2024, that in 2022, osteoporosis caused 2,659 deaths, equaling 10.2 deaths per 100,000 populace, accounting for 1.4% of total deaths. Hence, the escalating prevalence of osteoporosis is propelling the expansion of the osteoporosis drug market.

The osteoporosis drugs market covered in this report is segmented –

1) By Type: Bisphosphonates, Selective Estrogen Receptor Modulators (SERMs), RANK Ligand Inhibitors

2) By Administration: Oral, Injectable

3) By Distribution Channel: Retail Pharmacies, Hospital Pharmacies, Online Sales

4) By Application: Primary Osteoporosis, Secondary Osteoporosis

Subsegments:

1) By Bisphosphonates: Alendronate, Risedronate, Ibandronate, Zoledronic Acid

2) By Selective Estrogen Receptor Modulators (SERMs): Raloxifene, Bazedoxifene

3) By RANK Ligand Inhibitors: Denosumab

Which Emerging Trends And Strategic Shifts Are Shaping The Osteoporosis Drugs Market?

Leading corporations within the osteoporosis drugs market are progressing towards the adoption of creative solutions for this sector. For example, Apotex Inc., a pharmaceutical corporation anchored in Canada, introduced the Teriparatide Injectable for Osteoporosis Treatment in November 2023. This injectable method, which is a pre-filled pen containing 250 mcg/mL, can administer 28 daily doses of 20 mcg per pen and is designed for single-patient use. The introduction of this product offers a much-needed, cost-effective solution for patients.

Who Are The Main Participants Shaping The Osteoporosis Drugs Market Landscape?

Major companies operating in the osteoporosis drugs market include Pfizer Inc., F. Hoffmann La Roche Ltd., Merck & Co Inc., Novartis AG, Bristol Myers Squibb Company, GlaxoSmithKline PLC, Eli Lilly and Company, Amgen Inc., Novo Nordisk A/S, Asahi Kasei Pharma Corporation, Viatris Inc., Teva Pharmaceutical Industries Ltd, Mylan N.V., Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Ltd., Ipsen, Kyowa Kirin Co Ltd., Dr. Reddy’s Laboratories Ltd., Cipla Limited, Recordati S.p.A., Cadila Healthcare Ltd., Lupin Limited, Torrent Pharmaceuticals Ltd., Sunovion Pharmaceuticals Inc., Theramex, Radius Health Inc., Strides Pharma Science Limited, Apotex Inc.

https://www.thebusinessresearchcompany.com/report/osteoporosis-drugs-global-market-report

Which Region Currently Holds The Largest Share In The Osteoporosis Drugs Market?

North America was the largest region in the osteoporosis market in 2024. The regions covered in the osteoporosis drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=9102&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model